Skip to main content

Articles

Payers' Guide
Xiaflex (Collagenase Clostridium Histolyticum), First Drug Approved by the FDA for Peyronie’s Disease
Read More
Payers' Guide
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Read More
Conference Highlights ASH
The Single-Agent BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Responses Observed In All Mantle-Cell Lymphoma Patients
Read More
Conference Highlights ASH
Rituximab Maintenance Therapy after Autologous Stem-Cell Transplantation Prolongs Progression- Free Survival in Patients with Mantle-Cell Lymphoma
Read More
Conference Highlights ASH
Ibrutinib Overcomes Carfilzomib Resistance in Immunoproteasome-Deficient Mantle-Cell Lymphoma
Read More
Conference Highlights ASH
The RiBVD Regimen Offers a High Complete Response Rate in Elderly Patients with Untreated Mantle- Cell Lymphoma. Preliminary Results of the LYSA Trial “Lymphome Du Manteau 2010 SA”
Read More
Conference Highlights ASH
Lenalidomide, Bendamustine, and Rituximab as First-Line Therapy for Patients >65 Years with Mantle-Cell Lymphoma: Preliminary Results from the Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase 1-2 Trial
Read More
Conference Highlights ASH
Transplant for Mantle-Cell Lymphoma: Is it the Right Thing to Do?
Read More
Conference Highlights ASH
Combination Biologic Therapy Without Chemotherapy as Initial Treatment for Mantle-Cell Lymphoma: Multicenter Phase 2 Study of Lenalidomide Plus Rituximab
Read More
Conference Highlights ASH
Phase 2 Trial of GS-9973, a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Read More
Page 155 of 244
Results 1541 - 1550 of 2436